Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings
Ro 19-6327 (lazabemide, L), MDL 72974, selegiline, AGN 1135 and MDL 72145 were investigated for their MAO inhibitory effect in rat tissues in vitro. The selectivity of MAO-B inhibition of L, selegiline and MDL 72974 was also measured in vitro in human brain tissue as well as ex vivo in rat brain and liver after acute and subchronic administration. Of all compounds investigated L was the most selective for MAO-B inhibition under in vitro and ex vivo conditions. In volunteers, L completely but reversibly inhibited platelet MAO-B with a dose-dependent duration. Clinical trials with L are under way in both Alzheimer’s and Parkinson’s disease (PD).
KeywordsHuman Brain Tissue Nigrostriatal Dopaminergic Neuron Subchronic Administration Neurochemical Profile Selective Monoamine Oxidase
Unable to display preview. Download preview PDF.
- Bench CG, Prince GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, Bizière M, McClelland GR, Jamieson VL, Wood NB, Frackowiak RSJ (1991) Measurement of human cerebral mono-amine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibidor Ro 19-6327. Eur J Clin Pharmacol 40: 169–173.PubMedCrossRefGoogle Scholar
- Dingemanse J, Kettler R, Schmitt M, Fotteler B, Da Prada M (1991) Clinical pharmacology of selective inhibitors of MAO-B and COMT. Abstract F-19-05, 10th International Symposium on Parkinson’s Disease. October 27–30, Tokyo.Google Scholar
- Kettler R, Da Prada M (1989) Platelet MAO-B activity in humans and stump-tail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327’. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 213–219.CrossRefGoogle Scholar